Multicenter, Randomised, Placebo-controlled, Double Blinded, Parallel Arm Proof-of-concept Trial of Lixisenatide in Patients With Early Parkinson's Disease
Phase of Trial: Phase II
Latest Information Update: 06 Aug 2018
At a glance
- Drugs Lixisenatide (Primary)
- Indications Parkinson's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms LixiPark
- 27 Jul 2018 Status changed from not yet recruiting to recruiting.
- 30 May 2018 Planned End Date changed from 1 May 2021 to 1 Dec 2021.
- 30 May 2018 Planned primary completion date changed from 1 Mar 2021 to 1 Sep 2021.